Printer Friendly

IMMUNOMEDICS ELECTS ALBERT D. ANGEL TO BOARD OF DIRECTORS

 MORRIS PLAINS, N.J., June 3 /PRNewswire/ -- Immunomedics, Inc. (NASDAQ: IMMU) announced today the election of Albert D. Angel to the company's board of directors. Mr. Angel, 55, is vice president, public affairs, of Merck & Co., Inc. and president of The Merck Company Foundation. Mr. Angel has been with Merck since 1967, serving initially in various legal counsel positions and later as vice president of Merck Sharp & Dohme - Europe. Early in his career, Mr. Angel was an attorney at Hughes Hubbard Blair & Reed, and received his LL.B. from Yale Law School in 1960. This appointment increased Immunomedics' board to seven members.
 "It is with great pleasure that we welcome Mr. Angel to our board," commented Dr. David M. Goldenberg, Immunomedics' chairman of the board. "We are confident he will be an asset to our board, and will provide us with invaluable strategic advice as we move toward product commercialization."
 Mr. Angel commented that, "Immunomedics is in a very exciting stage of development, evidenced by its strong management team, full product pipeline, and underlying business potential. I am pleased to serve the company during this important period."
 Immunomedics is a biopharmaceutical company applying innovative technology in antibody selection, modification and chemistry to the development of products for the detection and treatment of cancers and infectious diseases. Integral to these products are highly specific monoclonal antibodies designed to deliver radioisotopes, chemotherapeutic agents or toxins to tumors and sites of infections or other diseases. The company currently has one therapeutic and five imaging products in human clinical trials. In addition, the company's colorectal cancer imaging agent, ImmuRAID(TM)-CEA, is under review for marketing approval by the U.S. Food and Drug Administration, as well as by regulatory agencies in Europe and Canada.
 -0- 6/3/93
 /CONTACT: Debra Wasser, director of corporate communications of Immunomedics, 201-605-1330, ext. 113/
 (IMMU)


CO: Immunomedics, Inc. ST: New Jersey IN: MTC SU: PER

SM-WB -- NY092 -- 5116 06/03/93 15:23 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jun 3, 1993
Words:327
Previous Article:NEWBRIDGE ANNOUNCES EXECUTIVE APPOINTMENTS
Next Article:MIDAS LAUNCHES INNOVATIVE CHILD CAR SEAT PROGRAM
Topics:


Related Articles
IMMUNOMEDICS RELEASES FIRST QUARTER EARNINGS; PROJECTS PROMISING RESULTS FOR 1992 AT ANNUAL MEETING
IMMUNOMEDICS ELECTS A. E. COHEN TO BOARD OF DIRECTORS AND PLANS TO APPOINT NEW PRESIDENT
IMMUNOMEDICS TO RESEARCH CANCER VACCINE UNDER FEDERAL GRANT
MEDCO RESEARCH ELECTS ALBERT ANGEL TO BOARD OF DIRECTORS
IMMUNOMEDICS ANNOUNCES MANAGEMENT CHANGES
Immunomedics Announces Board Changes
IBC Pharmaceuticals Elects Two Distinguished Scientists to Board of Directors.
Immunomedics Resale Shelf Registration Statement Declared Effective.
Immunomedics to Present at Rodman & Renshaw Techvest 7th Annual Healthcare Conference.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters